The Efficacy of Amoxapine as an Atypical Antipsychotic in an Acute Ketamine-Induced Rat Schizophrenia Model
Project Author
Issue Date
2024-04-03
Authors
Ornt, Haley
Loading...
Embargo
First Reader
Hollerman, Jeffrey R.
Additional Readers
Bertholomey, Megan L.
Keywords
schizophrenia , amoxapine , rat , ketamine , rodent , antipsychotic , atypical antipsychotic
item.page.distribution
Abstract
Poverty is a common issue amongst the schizophrenic population, which can make access to antipsychotic medications difficult. As a result, finding a cost-effective solution via medication, even without insurance, is imperative for the benefit of schizophrenic individuals who would not be able to obtain medications otherwise. Amoxapine is one such option in need of investigation. Amoxapine is typically utilized as a tricyclic antidepressant, however, literature has suggested the possibility of its effectiveness as an antipsychotic. The present study utilized acute ketamine administration as a pharmacological rodent model of schizophrenia. To establish efficacy as an atypical antipsychotic in a rodent model, a medication must treat positive, negative, and cognitive deficits without any extrapyramidal symptoms. Amoxapine would need to mitigate the effects of ketamine on locomotion, working memory, and social activity without causing extrapyramidal symptoms, such as akinesia or catalepsy, in order to be considered an effective atypical antipsychotic. Results found that amoxapine did not mitigate the deficits caused by ketamine administration. The only hypotheses supported were: amoxapine administration did not result in extrapyramidal symptoms and, for a select number of tests, acute ketamine administration was able to produce the proper deficits to suffice as a rodent schizophrenia model
Description
Collections
Chair
Major
Psychology
Neuroscience
Neuroscience
Department
Psychology
Neuroscience
Neuroscience
Recorder
License
Citation
Version
Honors
Neuroscience, 2024
Psychology, 2024
Psychology, 2024